Gabapentin Market Report and Forecast 2025-2034
Description
The global gabapentin market size was valued at USD 2.10 Billion in 2024, driven by the increasing use of gabapentin as a pain reliever drug across the globe. The market is anticipated to grow at a CAGR of 5.00% during the forecast period of 2025-2034 to achieve a value of USD 3.42 Billion by 2034.
Gabapentin: Introduction
Gabapentin tablets, capsules, and oral solutions are used to control seizures of certain type by combining them with other medications. They are also used as a pain reliever for postherpetic neuralgia that are basically the sensations or body aches occurring after person has had a shingle attack. It is also used to endure the pain of diabetic neuropathies and hot flashes in women who are undergoing treatment for breast cancer or the ones that have had their menopause.
Global Gabapentin Market Analysis
The major factors aiding the market growth are the undergoing development of new formulation for gabapentin in order to enhance efficacy and adherence of patient in the gabapentin market. The growing evidence of research towards the use of gabapentin to reduce alcohol dependence could possibly contribute to the expansion of the market. The escalating adoption of telemedicine, exploration of combination therapies is among some other key trends propelling the global gabapentin market expansion.
Additionally, the increased off-label prescription of gabapentin for conditions such as anxiety disorders, insomnia, and fibromyalgia, among others is also driving the demand for gabapentin. Due to the increasing geriatric population and lifestyle changes, the prevalence of chronic pain conditions such as neuropathic pain, postherpetic neuralgia, and diabetic neuropathy has also increased, owing to the market growth as gabapentin is the main prescribed drug for the treatment of such conditions. Because of its well-known opioid-sparing properties, gabapentin can be used to treat pain along with less potent opioids.
Gabapentin can potentially treat several anxiety disorders such as bipolar disorder, and other mental health conditions, which is why it has gained attention in the market. The growing emphasis on mental health and the need for effective pharmacological interventions are directly contributing to the global gabapentin market development.
Global Gabapentin Market Segmentations
The EMR’s report titled “Gabapentin Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Product Type
There are several major factors that are driving the market growth such as the increasing use of gabapentin as a pain reliever drug in the market. The rising incidence of chronic pains as shingles, diabetic neuropathy, and other pains that are hard to cure with the use of basic medicines are also contributing to the market growth.
Additionally, escalating demand for generic drug development which is comparatively less expensive than the drugs that are undersigned with name of big brands is propelling the growth of the market. Some other factors driving the market growth include the affordability and availability of Gabapentin in countries that are still developing with reasonable healthcare budgets. Gabapentin is available in different form as topical gels, oral solutions, capsules, tablets, and creams, and this factor is also a major driver for the gabapentin market growth. The increase in research and development to find new applications of gabapentin and develop new formulations to enhance the efficacy is a driver owing to the market growth.
Gabapentin has also been available in generic forms, which in turn is increasing competition among generic manufacturers. This competition would probably lead to lower prices and increased availability of gabapentin, driving market growth.
Gabapentin Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Gabapentin: Introduction
Gabapentin tablets, capsules, and oral solutions are used to control seizures of certain type by combining them with other medications. They are also used as a pain reliever for postherpetic neuralgia that are basically the sensations or body aches occurring after person has had a shingle attack. It is also used to endure the pain of diabetic neuropathies and hot flashes in women who are undergoing treatment for breast cancer or the ones that have had their menopause.
Global Gabapentin Market Analysis
The major factors aiding the market growth are the undergoing development of new formulation for gabapentin in order to enhance efficacy and adherence of patient in the gabapentin market. The growing evidence of research towards the use of gabapentin to reduce alcohol dependence could possibly contribute to the expansion of the market. The escalating adoption of telemedicine, exploration of combination therapies is among some other key trends propelling the global gabapentin market expansion.
Additionally, the increased off-label prescription of gabapentin for conditions such as anxiety disorders, insomnia, and fibromyalgia, among others is also driving the demand for gabapentin. Due to the increasing geriatric population and lifestyle changes, the prevalence of chronic pain conditions such as neuropathic pain, postherpetic neuralgia, and diabetic neuropathy has also increased, owing to the market growth as gabapentin is the main prescribed drug for the treatment of such conditions. Because of its well-known opioid-sparing properties, gabapentin can be used to treat pain along with less potent opioids.
Gabapentin can potentially treat several anxiety disorders such as bipolar disorder, and other mental health conditions, which is why it has gained attention in the market. The growing emphasis on mental health and the need for effective pharmacological interventions are directly contributing to the global gabapentin market development.
Global Gabapentin Market Segmentations
The EMR’s report titled “Gabapentin Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Product Type
- Capsule
- Tablet
- Epilepsy
- Neuropathic Pain
- Restless Legs Syndrome
- Oral
- Parenteral
- Intravenous
- Hospital Pharmacies
- Retail Pharmacies
- Other Distribution Channels
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
There are several major factors that are driving the market growth such as the increasing use of gabapentin as a pain reliever drug in the market. The rising incidence of chronic pains as shingles, diabetic neuropathy, and other pains that are hard to cure with the use of basic medicines are also contributing to the market growth.
Additionally, escalating demand for generic drug development which is comparatively less expensive than the drugs that are undersigned with name of big brands is propelling the growth of the market. Some other factors driving the market growth include the affordability and availability of Gabapentin in countries that are still developing with reasonable healthcare budgets. Gabapentin is available in different form as topical gels, oral solutions, capsules, tablets, and creams, and this factor is also a major driver for the gabapentin market growth. The increase in research and development to find new applications of gabapentin and develop new formulations to enhance the efficacy is a driver owing to the market growth.
Gabapentin has also been available in generic forms, which in turn is increasing competition among generic manufacturers. This competition would probably lead to lower prices and increased availability of gabapentin, driving market growth.
Gabapentin Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Zydus Pharmaceuticals, Inc.
- Glenmark Pharmaceuticals Limited
- Sun Pharmaceutical Industries Ltd.
- Ascend Laboratories, LLC
- Apotex Inc.
- Teva Pharmaceutical Industries Ltd.
- Aurobindo Pharma.
- Amneal Pharmaceuticals LLC.
- Cipla
- Pfizer Inc.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Gabapentin Market Overview
- 3.1 Global Gabapentin Market Historical Value (2018-2024)
- 3.2 Global Gabapentin Market Forecast Value (2025-2034)
- 4 Global Gabapentin Market Landscape
- 4.1 Image Guided Surgery: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Image Guided Surgery: Product Landscape
- 4.2.1 Analysis by Type
- 4.2.2 Analysis by Technology
- 4.2.3 Analysis by Route of Administration
- 5 Global Gabapentin Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.3 Porter’s Five Forces Model
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Gabapentin Market Segmentation
- 6.1 Global Gabapentin Market by Product Type
- 6.1.1 Market Overview
- 6.1.2 Capsule
- 6.1.3 Tablet
- 6.2 Global Gabapentin Market by Application
- 6.2.1 Market Overview
- 6.2.2 Epilepsy
- 6.2.3 Neuropathic Pain
- 6.2.4 Restless Legs Syndrome
- 6.3 Global Gabapentin Market by Route of Administration
- 6.3.1 Market Overview
- 6.3.2 Oral
- 6.3.3 Parenteral
- 6.3.4 Intravenous
- 6.4 Global Gabapentin Market by Distribution Channel
- 6.4.1 Market Overview
- 6.4.2 Hospital Pharmacies
- 6.4.3 Retail Pharmacies
- 6.4.4 Other Distribution Channels
- 6.5 Global Gabapentin Market by Region
- 6.5.1 Market Overview
- 6.5.2 North America
- 6.5.3 Europe
- 6.5.4 Asia Pacific
- 6.5.5 Latin America
- 6.5.6 Middle East and Africa
- 7 North America Gabapentin Market
- 7.1 Market Share by Country
- 7.2 United States of America
- 7.3 Canada
- 8 Europe Gabapentin Market
- 8.1 Market Share by Country
- 8.2 United Kingdom
- 8.3 Germany
- 8.4 France
- 8.5 Italy
- 8.6 Others
- 9 Asia Pacific Gabapentin Market
- 9.1 Market Share by Country
- 9.2 China
- 9.3 Japan
- 9.4 India
- 9.5 ASEAN
- 9.6 Australia
- 9.7 Others
- 10 Latin America Gabapentin Market
- 10.1 Market Share by Country
- 10.2 Brazil
- 10.3 Argentina
- 10.4 Mexico
- 10.5 Others
- 11 Middle East and Africa Gabapentin Market
- 11.1 Market Share by Country
- 11.2 Saudi Arabia
- 11.3 United Arab Emirates
- 11.4 Nigeria
- 11.5 South Africa
- 11.6 Others
- 12 Regulatory Framework
- 12.1 Regulatory Overview
- 12.1.1 US FDA
- 12.1.2 EU EMA
- 12.1.3 INDIA CDSCO
- 12.1.4 JAPAN PMDA
- 12.1.5 Others
- 13 Patent Analysis
- 13.1 Analysis by Type of Patent
- 13.2 Analysis by Publication year
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Patent Age
- 13.5 Analysis by CPC Analysis
- 13.6 Analysis by Patent Valuation
- 13.7 Analysis by Key Players
- 14 Grants Analysis
- 14.1 Analysis by year
- 14.2 Analysis by Amount Awarded
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Grant Application
- 14.5 Analysis by Funding Institute
- 14.6 Analysis by NIH Departments
- 14.7 Analysis by Recipient Organization
- 15 Clinical Trials Analysis
- 15.1 Analysis by Trial Registration Year
- 15.2 Analysis by Trial Status
- 15.3 Analysis by Trial Phase
- 15.4 Analysis by Therapeutic Area
- 15.5 Analysis by Geography
- 16 Funding and Investment Analysis
- 16.1 Analysis by Funding Instances
- 16.2 Analysis by Type of Funding
- 16.3 Analysis by Funding Amount
- 16.4 Analysis by Leading Players
- 16.5 Analysis by Leading Investors
- 16.6 Analysis by Geography
- 17 Partnership and Collaborations Analysis
- 17.1 Analysis by Partnership Instances
- 17.2 Analysis by Type of Partnership
- 17.3 Analysis by Leading Players
- 17.4 Analysis by Geography
- 18 Supplier Landscape
- 18.1 Zydus Pharmaceuticals, Inc.
- 18.1.1 Financial Analysis
- 18.1.2 Product Portfolio
- 18.1.3 Demographic Reach and Achievements
- 18.1.4 Mergers and Acquisitions
- 18.1.5 Certifications
- 18.2 Glenmark Pharmaceuticals Limited
- 18.2.1 Financial Analysis
- 18.2.2 Product Portfolio
- 18.2.3 Demographic Reach and Achievements
- 18.2.4 Mergers and Acquisitions
- 18.2.5 Certifications
- 18.3 Sun Pharmaceutical Industries Ltd.
- 18.3.1 Financial Analysis
- 18.3.2 Product Portfolio
- 18.3.3 Demographic Reach and Achievements
- 18.3.4 Mergers and Acquisitions
- 18.3.5 Certifications
- 18.4 Ascend Laboratories, LLC
- 18.4.1 Financial Analysis
- 18.4.2 Product Portfolio
- 18.4.3 Demographic Reach and Achievements
- 18.4.4 Mergers and Acquisitions
- 18.4.5 Certifications
- 18.5 Apotex Inc.
- 18.5.1 Financial Analysis
- 18.5.2 Product Portfolio
- 18.5.3 Demographic Reach and Achievements
- 18.5.4 Mergers and Acquisitions
- 18.5.5 Certifications
- 18.6 Teva Pharmaceutical Industries Ltd.
- 18.6.1 Financial Analysis
- 18.6.2 Product Portfolio
- 18.6.3 Demographic Reach and Achievements
- 18.6.4 Mergers and Acquisitions
- 18.6.5 Certifications
- 18.7 Aurobindo Pharma.
- 18.7.1 Financial Analysis
- 18.7.2 Product Portfolio
- 18.7.3 Demographic Reach and Achievements
- 18.7.4 Mergers and Acquisitions
- 18.7.5 Certifications
- 18.8 Amneal Pharmaceuticals LLC.
- 18.8.1 Financial Analysis
- 18.8.2 Product Portfolio
- 18.8.3 Demographic Reach and Achievements
- 18.8.4 Mergers and Acquisitions
- 18.8.5 Certifications
- 18.9 Cipla
- 18.9.1 Financial Analysis
- 18.9.2 Product Portfolio
- 18.9.3 Demographic Reach and Achievements
- 18.9.4 Mergers and Acquisitions
- 18.9.5 Certifications
- 18.10 Pfizer Inc.
- 18.10.1 Financial Analysis
- 18.10.2 Product Portfolio
- 18.10.3 Demographic Reach and Achievements
- 18.10.4 Mergers and Acquisitions
- 18.10.5 Certifications
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
- 20.1 Very Small Companies
- 20.2 Small Companies
- 20.3 Mid-Sized Companies
- 20.4 Large Companies
- 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
- 21.1 Government Funded
- 21.2 Private Insurance
- 21.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
